Management of symptomatic patients with suspected mild-moderate COVID-19 in general practice. What was published within the first year of the pandemic? A scoping review

References

• WHO. Rolling updates on coronavirus disease (COVID-19) [cited 2021 Oct 28]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen
   Google Scholar
• Yang S, Li A, Eshaghpour A, et al. Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19. BMJ Evid Based Med. 2020. doi: 10.1136/bmjebm-2020-111499
   Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalisation and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468–1481.
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult in-patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;6736:1–9.
   Google Scholar
• David HJ, Wichor M, Patrick JE, et al. Development and validation of search filters to identify articles on family medicine in online medical databases. Ann Fam Med. 2015;13:364–366.
   PubMed Web of Science ®Google Scholar
• Guyatt G, Rennie D, Meade MO, et al. Users’ guides to the medical literature: a manual for evidence-based clinical practice. New York: McGraw-Hill Education; 2015.
   Google Scholar
• Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomised, controlled trial. Clin Infect Dis. 2020: ciaa1009.
   PubMed Web of Science ®Google Scholar
• Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in non-hospitalised adults with early COVID-19: a randomised trial. Ann Intern Med. 2020;173(8):623–631.
   PubMed Web of Science ®Google Scholar
• Agusti A, Guillen E, Ayora A, et al. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomised trial. Enferm Infecc Microbiol Clin (Engl Ed). 2020;S0213-005X(20)30413-4.
   Google Scholar
• Sogut O, Can MM, Guven R, et al. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot observational study. Am J Emerg Med. 2021;40:41–46.
   PubMed Web of Science ®Google Scholar
• Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild covid-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021;58(1):2003725.
   PubMed Web of Science ®Google Scholar
• López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. J Am Med Assoc. 2021;325(14):1426–1435.
   PubMed Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N Engl J Med. 2021;384(3):229–237.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–251.
   PubMed Web of Science ®Google Scholar
• Cadegiani FA, McCoy J, Gustavo Wambier C, et al. Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and time-to-remission in males with COVID-19: a randomised, double-blind, placebo-controlled interventional trial (EAT-DUTA AndroCoV trial – biochemical). Cureus. 2021;13(2):e13047.
   Google Scholar
• Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021;9(5):498–510.
   PubMed Web of Science ®Google Scholar
• Cadegiani FA, McCoy J, Gustavo Wambier C, et al. Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomised, double-blinded, placebo-controlled trial. Cureus. 2021;2:1–8.
   Google Scholar
• Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomised placebo-controlled trial. Nat Commun. 2021;12(1):1–10.
   PubMed Web of Science ®Google Scholar
• Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. Clin Microbiol Infect. 2021;27(2):285.e1–285.e4.
   PubMed Web of Science ®Google Scholar
• Skolimowska K, Rayment M, Jones R, et al. Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence. Clin Microbiol Infect. 2020;26(12):1711–1713.
   PubMed Web of Science ®Google Scholar
• Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. J Clin Virol. 2020;130:104567.
   PubMed Web of Science ®Google Scholar
• Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, The Netherlands, march 2020. Euro Surveill. 2020;25(16):2000508.
   PubMedGoogle Scholar
• Vaes AW, Machado FVC, Meys R, et al. Care dependency in non-hospitalised patients with COVID-19. JCM. 2020;9(9):2946.
   Web of Science ®Google Scholar
• Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-2020.
   PubMedGoogle Scholar
• Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–631.
   PubMed Web of Science ®Google Scholar
• Rubin JE, Crowe SE. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2020;172(1):ITC1–ITC14.
   PubMed Web of Science ®Google Scholar
• Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–2090.
   PubMed Web of Science ®Google Scholar
• McMichael TM, Currie DW, Clark S, et al. Epidemiology of covid-19 in a long-term care facility in King county, Washington. N Engl J Med. 2020;382(21):2005–2011.
   PubMed Web of Science ®Google Scholar
• PRISMA. PRISMA for scoping reviews. Transparent Report. Syst. Rev. Meta-Analsyses; 2015 [cited 2021 Oct 28]. Available from: http://www.prisma-statement.org/Extensions/ScopingReviews
   Google Scholar
• Lazarus JV, Palayew A, Rasmussen LN, et al. Searching PubMed to retrieve publications on the COVID-19 pandemic: comparative analysis of search strings. J Med Internet Res. 2020;22(11):e23449.
   PubMed Web of Science ®Google Scholar
• Eythorsson E, Helgason D, Ingvarsson RF, et al. Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study. BMJ 2020;371:m4529.
   Google Scholar
• Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020;369:m1328.
   PubMed Web of Science ®Google Scholar
• Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020;7(7):CD013665.
   PubMed Web of Science ®Google Scholar
• Singh B, Ryan H, Kredo T, et al. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021;2:CD013587.
   PubMed Web of Science ®Google Scholar
• Siemieniuk RAC, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. Br Med J. 2020;370:m2980.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772.
   PubMed Web of Science ®Google Scholar
• Shallcross L, Burke D, Abbott O, et al. Factors associated with SARS-CoV-2 infection and outbreaks in long-term care facilities in England: a national cross-sectional survey. Lancet Heal Longev. 2021;2(3):e129–e142.
   PubMedGoogle Scholar